查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1541405

2024-2032 年按产品类型、应用、最终用途和地区分類的放射性药物市场报告

Radiopharmaceuticals Market Report by Product Type, Application, End Use, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年，全球放射性药物市场规模达到55亿美元。放射性药物市场主要由影像技术的新兴技术进步、慢性病发病率的增加以及全球政府实施有利的监管标准所推动。

放射性药物市场分析：

主要市场驱动因素：根据放射性药物市场研究报告，该市场主要受到慢性病发病率不断上升的推动，主要是癌症和心血管疾病。此外，包括 PET 和 SPECT 在内的影像技术的进步，随着这些放射性药物在诊断方面的使用激增，改变了诊断技能。

主要市场趋势：该行业正在形成的趋势是人们越来越偏好治疗诊断学，即相同的化合物可用于诊断和治疗。此外，放射性药物产业概况显示了对研发（R&D）的投资，以引入新型放射性药物，以提高疗效并最大限度地减少副作用。

地理趋势：由于强大的医疗基础设施、高支出和支持性的监管环境，北美地区引领全球市场。由于卫生支出的增加以及对核医学益处的认识的增加，预计包括中国和印度在内的亚太新兴经济体将快速成长。

竞争格局：放射性药物产业的一些主要市场参与者包括 Advanced Accelerator Applications (Novartis AG)、Bayer AG、Bracco SpA、Cardinal Health Inc.、Curium Pharma、General Electric Company、IBA RadioPharma Solutions、Jubilant Pharma Limited、Lantheus Medical Imaging Inc、Nordion Inc. (Sotera Health)、NTP Radioisotopes SOC Ltd、PharmaLogic Holdings Corp. 和西门子AG 等。

挑战与机会：放射性药物审批过程与监管挑战相关，例如製造过程的复杂性和安全威胁。然而，放射性药物市场预测良好，市场参与者前景良好。人们对个人化医疗的兴趣日益浓厚，以及放射性药物作为标靶治疗的一部分的出现，促进了市场的成长。透过与科研院所的合作、企业间的合作，为医药企业提供了广大的市场开拓机会。

放射性药物市场趋势：

成像技术的技术进步：

正子断层扫描（PET）和单光子发射电脑断层扫描（SPECT）等影像技术的进步极大地增强了放射性药物的诊断性质。使用这些技术对于肿瘤学、神经学和心臟病学中需要早期治疗或预防措施的疾病进行早期诊断至关重要。例如，2023 年，正子断层扫描 (PET) 的全球市场价值约为 119.61 万美元。目前，根据 IMARC GROUP 的预测，到 2032 年，全球正子断层扫描 (PET) 市场预计将成长至约 19.3 亿美元，2024 年至 2032 年的年复合成长率(CAGR) 为 5.33%。这一增长归功于成像技术的进步以及这些先进系统在世界各地医疗诊断中的实施。

慢性病盛行率增加：

由于全球癌症、心血管疾病和神经系统疾病的盛行率不断上升，对放射性药物的需求不断增加，推动了市场的成长。这些疾病需要准确的诊断影像和针对性的治疗，促使放射性药物在临床实践中的使用。根据疾病管制与预防中心 2020 年的资料，美国报告了 1,603,844 例新发癌症病例，并因此不幸失去了 602,347 人的生命。这相当于每 10 万人中有 403 例新癌症病例和 144 例癌症相关死亡。目前，放射性药物用于癌症早期检测和治疗所需的诊断和治疗应用，从而推动市场成长。

有利的监管环境：

该行业受到政府行为和监管规定的显着影响。例如，美国食品药物管理局 (FDA) 和欧洲药品管理局 (EMA) 等监管机构根据国家医学图书馆的规定，提出即时有效的程序来批准新开发的放射性药物，鼓励创新和投资。除此之外，对药物类别进行快速虚拟审查的可能性，以及获得孤儿药指定 (ODD) 状态的经济激励，激励许多製药公司参与新放射性药物疗法的研发 (R&D)。

放射性药物市场细分：

IMARC Group提供了每个细分市场的主要趋势分析，以及 2024-2032 年全球、区域和国家层面的预测。我们的报告根据产品类型、应用和最终用途对市场进行了分类。

按产品类型划分：

诊断核子医学

治疗核子医学

诊断核医学占大部分市场份额

该报告根据产品类型对市场进行了详细的细分和分析。这包括诊断核子医学和治疗核子医学。报告称，诊断核子医学占最大部分。

诊断核子医学是指使用通常用于影像的多种放射性药物。它结合了不同的模式，例如正子断层扫描（PET）。这同样适用于单光子发射电脑断层扫描 (SPECT)。由于癌症、心臟异常和其他神经疾病等疾病盛行率的增加，诊断核医市场在未来几年必定会扩大。目前，那格浦尔政府医学院和医院（GMCH）和超级专科医院（SSH）正准备透过设立专门的核子医学部门来提高其诊断能力。今年，该部门的提案获得了地区规划委员会 (DPC) 的批准，预算为 9.5 亿卢比。由于行政部分已经整理完毕，部门建设即将启动。

按应用划分：

肿瘤学

心臟病学

神经病学

内分泌科

其他的

肿瘤学占产业最大份额

报告还提供了基于应用程式的详细市场细分和分析。这包括肿瘤学、心臟病学、神经学、内分泌学等。报告称，肿瘤学占据最大的市场份额。

由于癌症标靶治疗和精准医疗市场的快速成长，放射性药物的肿瘤学应用需求不断增长。放射性药物对于透过 PET 和 SPECT 扫描等方式进行癌症的诊断、分期和治疗后评估至关重要。这也归因于不断扩大的放射肿瘤学市场，据 IMARC GROUP 称，该市场预计到 2032 年将达到 145 亿美元，2024-2032 年期间的复合年增长率 (CAGR) 为 6.5%。除此之外，为提高肿瘤学放射性药物的可行性和安全性而进行的持续研究和开发工作预计将推动该行业的发展势头。

按最终用途细分：

医院和诊所

研究所

诊断中心

诊断中心代表领先的细分市场

该报告根据最终用途提供了详细的市场细分和分析。这包括医院和诊所、研究机构和诊断中心。根据该报告，诊断中心占最大部分。

诊断中心是最大的细分市场，正在创造有利的放射性药物市场前景。为了实现对各种医疗状况的准确诊断，对核子造影程序的需求不断增长，导致了诊断中心的采用。它使用各种成像技术，例如正电子发射断层扫描 (PET)、单光子发射电脑断层扫描 (SPECT) 和混合成像，以确保良好的患者治疗效果。因此，各个主要参与者正在引入先进的诊断技术，这进一步扩大了放射性药物的市场价值。例如，2022 年 12 月，领先的医学影像技术公司 Polarean Imaging plc 宣布美国食品药物管理局 (FDA) 批准了 XENOVIEW。它是一种超极化造影剂，适用于磁振造影 (MRI)，以评估成人和 12 岁及以上儿童患者的肺部通气。 XENOVIEW 代表了肺部医学的新时代，因为它是第一种吸入式 MRI 超极化造影剂。它使得获得肺部通气的新颖可视化成为可能，而无需使患者暴露于电离辐射及其相关风险。它透过 Polarean HPX 超极化系统进行管理，XENOVIEW 在一次 10-15 秒屏气 MRI 练习中进行分配。

按地区划分：

北美洲

美国

加拿大

亚太

中国

日本

印度

韩国

澳洲

印尼

其他的

欧洲

德国

法国

英国

义大利

西班牙

俄罗斯

其他的

拉丁美洲

巴西

墨西哥

其他的

中东和非洲

北美市场领先，占据最大的放射性药物市场份额

该报告还对所有主要区域市场进行了全面分析，其中包括北美（美国和加拿大）；欧洲（德国、法国、英国、义大利、西班牙、俄罗斯等）；亚太地区（中国、日本、印度、韩国、澳洲、印尼等）；拉丁美洲（巴西、墨西哥等）；以及中东和非洲。报告称，北美是放射性药物最大的区域市场。

由于强大的医疗基础设施、高额医疗支出、技术进步以及市场上拥有众多产品的成熟企业的存在，北美在市场上占据主导地位。根据医疗保险和医疗补助服务中心的数据，2022 年美国医疗保健支出成长 4.1%，达到 4.5 兆美元，高于 2021 年 3.2% 的增幅。历史新高），私人医疗保险投保人数增加了290 万人，医疗补助参保人数增加了610 万人。此外，政府的高额资助和支持以及疾病盛行率的增加也推动了市场的成长。因此，这促进了该行业的创新，并加速了新的有效产品的推出，从而提高了放射性药物市场的成长率。

竞争格局：

市场研究报告也对市场竞争格局进行了全面分析。也提供了所有主要公司的详细资料。放射性製药业的一些主要市场参与者包括 Advanced Accelerator Applications (Novartis AG)、Bayer AG、Bracco SpA、Cardinal Health Inc.、Curium Pharma、通用电气公司、IBA RadioPharma Solutions、Jubilant Pharma Limited、Lantheus Medical Imaging Inc.、 Nordion Inc. (Sotera Health)、NTP Radioisotopes SOC Ltd、PharmaLogic Holdings Corp. 和西门子AG。

（请注意，这只是关键参与者的部分列表，报告中提供了完整列表。）

目前，放射性药物市场的主要参与者都参与了各种策略性倡议，以维持其市场地位和立足点。这些措施包括研发投资，以开发和创新具有更高功效和安全性的新放射性药物产品。除了研究、开发和创新外，两家公司还参与策略合作和伙伴关係，以扩大其产品线和分销网络。例如，2023 年 11 月，总部位于威斯康辛州的融合技术公司 SHINE Technologies 最近与 Nucleus RadioPharma 签订了长期供应协议，供应铠 177。放射性同位素用于癌症治疗疗法，包括正在开发的神经内分泌肿瘤、前列腺癌和其他实体肿瘤的疗法。几年来，SHINE 将供应 Lu-177 以支持 Nucleus RadioPharma 的放射性配体治疗 (RLT) 产品，该产品针对专门针对神经内分泌肿瘤和前列腺癌设计的放射性药物治疗。一些主要参与者也参与增强和优化製造生产流程，以满足对放射性药物不断增长的需求，符合即将推出和现有的监管标准。

放射性药物市场新闻：

2023 年 3 月：国际原子能总署 (IAEA) 与 11 所日本大学和机构合作发起「希望之光」合作伙伴关係，旨在加强亚太地区的癌症照护服务。

2024 年 2 月：百时美施贵宝完成了对 RayzeBio 的收购，透过独特的基于锕的放射性药物平台增强了其产品组合。此次新增也引入了放射性药物治疗（RPT），它正在成为治疗患者实体瘤的成长最快的治疗方式之一。

本报告回答的关键问题

  • 2023年全球放射性药物市场规模是多少
  • 2024-2032年全球放射性药物市场的预期成长率是多少
  • COVID-19 对全球放射性药物市场有何影响
  • 推动全球放射性药物市场的关键因素是什么
  • 根据产品类型，全球放射性药物市场的细分如何
  • 基于应用的全球放射性药物市场的细分是什么
  • 根据最终用途，全球放射性药物市场的细分情况如何
  • 全球放射性药物市场的重点区域有哪些
  • 谁是全球放射性药物市场的主要参与者/公司

本报告回答的关键问题

  • 2023年全球放射性药物市场规模有多大？ 2024-2032年全球放射性药物市场的预期成长率是多少？
  • COVID-19 对全球放射性药物市场有何影响？
  • 推动全球放射性药物市场的关键因素是什么？
  • 根据产品类型，全球放射性药物市场的细分情况如何？
  • 根据应用，全球放射性药物市场的细分情况如何？
  • 根据最终用途，全球放射性药物市场的细分情况如何？
  • 全球放射性药物市场的重点区域有哪些？
  • 谁是全球放射性药物市场的主要参与者/公司？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球放射性药物市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依产品类型

  • 诊断核子医学
    • 市场趋势
    • 市场预测
  • 治疗核子医学
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：按应用

  • 肿瘤学
    • 市场趋势
    • 市场预测
  • 心臟病学
    • 市场趋势
    • 市场预测
  • 神经病学
    • 市场趋势
    • 市场预测
  • 内分泌科
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：最终用途别

  • 医院和诊所
    • 市场趋势
    • 市场预测
  • 研究所
    • 市场趋势
    • 市场预测
  • 诊断中心
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Advanced Accelerator Applications (Novartis AG)
    • Bayer AG
    • Bracco SpA
    • Cardinal Health Inc.
    • Curium Pharma
    • General Electric Company
    • IBA RadioPharma Solutions
    • Jubilant Pharma Limited
    • Lantheus Medical Imaging Inc
    • Nordion Inc. (Sotera Health)
    • NTP Radioisotopes SOC Ltd
    • PharmaLogic Holdings Corp.
    • Siemens AG
Product Code: SR112024A3906

The global radiopharmaceuticals market size reached US$ 5.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 8.7 Billion by 2032, exhibiting a growth rate (CAGR) of 5.1% during 2024-2032. The radiopharmaceuticals market is primarily driven by the emerging technological advancements in imaging technology, the increasing incidences of chronic ailments, and the implementation of favorable regulatory standards by the government across the globe.

Radiopharmaceuticals Market Analysis:

Major Market Drivers: As per the radiopharmaceuticals market research report, the market is predominantly driven by the growing incidence of chronic diseases, mainly cancer and cardiovascular disorders. Additionally, advances in imaging procedures including PET and SPECT alter the diagnosis skill with the surging use of these radiopharmaceuticals for diagnostic perspectives.

Key Market Trends: The trend that is taking shape in the industry is the growing preference for theranostics, where the same compound can be used for diagnosis and therapy. Furthermore, the radiopharmaceuticals industry overview shows investments in research and development (R&D) to introduce novel radiopharmaceuticals to inflate efficacy and minimize side effects.

Geographical Trends: The North America region leads the global market as a result of the strong healthcare infrastructure, high expenditure, and supportive regulatory environment. It is also expected that emerging economies in Asia-Pacific including China and India will grow rapidly due to the increase in health expenditure and awareness concerning the benefits of nuclear medicine.

Competitive Landscape: Some of the major market players in the radiopharmaceuticals industry include Advanced Accelerator Applications (Novartis AG), Bayer AG, Bracco S.p.A., Cardinal Health Inc., Curium Pharma, General Electric Company, IBA RadioPharma Solutions, Jubilant Pharma Limited, Lantheus Medical Imaging Inc, Nordion Inc. (Sotera Health), NTP Radioisotopes SOC Ltd, PharmaLogic Holdings Corp. and Siemens AG, among many others.

Challenges and Opportunities: The radiopharmaceutical approval process is associated with regulatory challenges, such as the complexity of manufacturing processes and safety threats. However, the radiopharmaceuticals market forecast is favorable and market players have good prospects. The growing interest in personalized medicine and the emergence of radiopharmaceuticals as a component of targeted therapy contribute to the market growth. It offers vast opportunities for market development through collaboration with research institutes and intercompany cooperation for pharmaceutical enterprises.

Radiopharmaceuticals Market Trends:

Technological Advancements in Imaging Technologies:

The advancements in imaging technologies, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), have highly enhanced the diagnostic nature of radiopharmaceuticals. It is vital in the early diagnosis of conditions that require early treatment or preventive measures in oncology, neurology, and cardiology, using these technologies. For instance, in 2023, the global market for positron emission tomography (PET) was valued at approximately $1.196.1 Million. Presently, the global positron emission tomography (PET) market is projected to grow to about $1.93 billion by 2032, with a compound annual growth rate (CAGR) of 5.33% from 2024 through 2032, according to forecasts by the IMARC GROUP. The growth is attributed to advances in imaging technology and the implementation of these advanced systems in medical diagnostics across the world.

Increasing Prevalence of Chronic Diseases:

The market growth is driven by the increasing demand for radiopharmaceuticals due to the rising prevalence of cancer, cardiovascular diseases, and neurological disorders worldwide. These diseases necessitate accurate diagnostic imaging and focused therapeutics, prompting the utilization of radiopharmaceuticals in clinical practice. According to CENTERS for DISEASE CONTROL AND PREVENTION data in 2020, the United States witnessed the reporting of 1,603,844 new incidences of cancer and the unfortunate loss of 602,347 lives due to the disease. This equates to a rate of 403 new cancer cases and 144 cancer-related deaths per 100,000 individuals. Currently, radiopharmaceuticals are used in diagnostic and treatment applications necessary for the early detection and treatment of cancers, thus driving market growth.

Favorable Regulatory Environment:

The industry is significantly impacted by governmental actions and regulatory provisions. For instance, regulatory authorities such as the U.S. FOOD AND DRUG ADMINISTRATION (FDA) and the EUROPEAN MEDICINES AGENCY (EMA) present instant and effective procedures to approve newly developed radiopharmaceuticals encouraging innovation and investment as per the NATIONAL LIBRARY of MEDICINE. Besides this, the possibility of a rapid virtual review of drug classes, along with financial incentives for obtaining Orphan Drug Designation (ODD) status, motivates many pharmaceutical companies to engage in research and development (R&D) of new radiopharmaceutical therapies.

Radiopharmaceuticals Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product type, application, and end use.

Breakup by Product Type:

Diagnostic Nuclear Medicine

Therapeutic Nuclear Medicine

Diagnostic nuclear medicine accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the product type. This includes diagnostic nuclear medicine and therapeutic nuclear medicine. According to the report, diagnostic nuclear medicine represented the largest segment.

Diagnostic nuclear medicine refers to the administration of a diverse number of radiopharmaceuticals typically used for imaging. It incorporates different modalities such as positron emission tomography (PET). The same also applies to single-photon emission computed tomography (SPECT). Due to the observed increase in the prevalence of diseases including cancer, cardiac abnormalities, and other neuronal conditions, the diagnostic nuclear medicine market is bound to expand in the coming years. At present, the Government Medical College and Hospital (GMCH) and the Super Speciality Hospital (SSH) in Nagpur are preparing to elevate their diagnostic capabilities by launching a dedicated nuclear medicine department. The proposal for this department was approved by the District Planning Committee (DPC) this year with a 9.5 crore budget. Since the administrative part has been sorted, the construction of the department is to be initiated soon.

Breakup by Application:

Oncology

Cardiology

Neurology

Endocrinology

Others

Oncology holds the largest share of the industry

A detailed breakup and analysis of the market based on the application have also been provided in the report. This includes oncology, cardiology, neurology, endocrinology, and others. According to the report, oncology accounted for the largest market share.

Oncology applications in radiopharmaceuticals are experiencing rising demand, facilitated by the rapid growth of the targeted cancer therapies and precision medicine market. Radiopharmaceuticals are crucial in the diagnosis, staging, and post-treatment evaluation of cancers through PET and SPECT scans, among other modalities. This is also attributed to the expanding radiation oncology market which is expected to reach US$ 14.5 Billion by 2032, exhibiting a growth rate (CAGR) of 6.5% during 2024-2032 as stated by IMARC GROUP. Apart from this, ongoing research and development efforts to improve the feasibility and safety of radiopharmaceuticals in oncology are anticipated to boost the momentum of the sector.

Breakup by End Use:

Hospitals and Clinics

Research Institutes

Diagnostic Centers

Diagnostic centers represent the leading market segment

The report has provided a detailed breakup and analysis of the market based on the end use. This includes hospitals and clinics, research institutes, and diagnostic centers. According to the report, diagnostic centers represented the largest segment.

Diagnostic centers represent the largest segment and are creating a favorable radiopharmaceuticals market outlook. The rising demand for nuclear imaging procedures to achieve an accurate diagnosis of various medical conditions resulted in the adoption of diagnostic centers. It uses various imaging techniques such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), and hybrid imaging to ensure a favorable patient outcome. Hence various key players are introducing advanced diagnostic technologies which is further expanding the radiopharmaceuticals market value. For instance, in December 2022, Polarean Imaging plc, a leading medical imaging technology company, announced that the U.S. Food and Drug Administration (FDA) approved XENOVIEW. It is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) to assess lung ventilation in adults and pediatric patients 12 years of age and older. XENOVIEW represents a new era of pulmonary medicine since it is the very first inhaled MRI hyperpolarized contrast agent. It makes it possible to obtain a novel visualization of lung ventilation without exposing the patient to ionizing radiation and its associated risks. It is administered via the Polarean HPX hyperpolarization system, XENOVIEW is dispensed in a single 10-15 second breath hold MRI practice.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest radiopharmaceuticals market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for radiopharmaceuticals.

North America is dominating the market due to the presence of strong healthcare infrastructure, high healthcare spending, technological advancements, and the presence of established players within the market with numerous product offerings. According to the CENTERS FOR MEDICARE & MEDICAID SERVICES, United States health care spending grew 4.1% to reach $4.5 trillion in 2022, faster than the increase of 3.2% in 2021. Moreover, in 2022, the insured share of the population reached 92% (a historic high) and private health insurance enrollment increased by 2.9 million individuals and Medicaid enrollment increased by 6.1 million individuals. In addition, high government funding and support, as well as an increasing prevalence of disease, are also driving the market growth. Hence, this promotes innovation within the sector and accelerates the introduction of new and effective products generating an increasing radiopharmaceuticals market growth rate.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the radiopharmaceuticals industry include Advanced Accelerator Applications (Novartis AG), Bayer AG, Bracco S.p.A., Cardinal Health Inc., Curium Pharma, General Electric Company, IBA RadioPharma Solutions, Jubilant Pharma Limited, Lantheus Medical Imaging Inc, Nordion Inc. (Sotera Health), NTP Radioisotopes SOC Ltd, PharmaLogic Holdings Corp. and Siemens AG.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Currently, key players in the radiopharmaceuticals market are involved in various strategic initiatives to sustain their market positions and footholds. These initiatives include research and development investments to develop and innovate new radiopharmaceutical products with enhanced efficacies and safety. In addition to research, development, and innovation, the companies are also involved in strategic collaborations and partnerships to expand their product pipeline and distribution networks. For instance, in November 2023, SHINE Technologies, a fusion technology company based in Wisconsin, has recently entered a long-term supply agreement with Nucleus RadioPharma to supply lutetium-177. A radioisotope is utilized in cancer treatment therapies, including those under development for neuroendocrine tumors, prostate cancer, and other solid tumors. For several years, SHINE will supply Lu-177 to support Nucleus RadioPharma's radioligand therapy (RLT) offerings, which target radiopharmaceutical treatments specifically designed for neuroendocrine tumors and prostate cancer. Some key players are also involved in enhancing and optimizing manufacturing production processes to meet the growing demand for radiopharmaceuticals in line with upcoming and existing regulatory standards.

Radiopharmaceuticals Market News:

March 2023: The INTERNATIONAL ATOMIC ENERGY AGENCY (IAEA) initiates the Rays of Hope partnership in collaboration with 11 Japanese universities and institutions which aims to bolster cancer care services across Asia and the Pacific region.

February 2024: Bristol Myers Squibb finalized the acquisition of RayzeBio, enhancing its portfolio with a distinctive actinium-based radiopharmaceutical platform. This addition also introduces radiopharmaceutical therapeutics (RPTs), which are emerging as one of the most rapidly growing treatment modalities for addressing solid tumors in patients.

Key Questions Answered in This Report

  • 1. What was the size of the global radiopharmaceuticals market in 2023?
  • 2. What is the expected growth rate of the global radiopharmaceuticals market during 2024-2032?
  • 3. What has been the impact of COVID-19 on the global radiopharmaceuticals market?
  • 4. What are the key factors driving the global radiopharmaceuticals market?
  • 5. What is the breakup of the global radiopharmaceuticals market based on the product type?
  • 6. What is the breakup of the global radiopharmaceuticals market based on the application?
  • 7. What is the breakup of the global radiopharmaceuticals market based on the end use?
  • 8. What are the key regions in the global radiopharmaceuticals market?
  • 9. Who are the key players/companies in the global radiopharmaceuticals market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Radiopharmaceuticals Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Diagnostic Nuclear Medicine
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Therapeutic Nuclear Medicine
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Oncology
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cardiology
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Neurology
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Endocrinology
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End Use

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Research Institutes
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Diagnostic Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Advanced Accelerator Applications (Novartis AG)
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Bayer AG
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bracco S.p.A.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 SWOT Analysis
    • 14.3.4 Cardinal Health Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Curium Pharma
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 General Electric Company
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 IBA RadioPharma Solutions
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Jubilant Pharma Limited
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Lantheus Medical Imaging Inc
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Nordion Inc. (Sotera Health)
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 SWOT Analysis
    • 14.3.11 NTP Radioisotopes SOC Ltd
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
    • 14.3.12 PharmaLogic Holdings Corp.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
    • 14.3.13 Siemens AG
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Radiopharmaceuticals Market: Major Drivers and Challenges
  • Figure 2: Global: Radiopharmaceuticals Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Radiopharmaceuticals Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Radiopharmaceuticals Market: Breakup by Product Type (in %), 2023
  • Figure 5: Global: Radiopharmaceuticals Market: Breakup by Application (in %), 2023
  • Figure 6: Global: Radiopharmaceuticals Market: Breakup by End Use (in %), 2023
  • Figure 7: Global: Radiopharmaceuticals Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Radiopharmaceuticals (Diagnostic Nuclear Medicine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Radiopharmaceuticals (Diagnostic Nuclear Medicine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Radiopharmaceuticals (Therapeutic Nuclear Medicine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Radiopharmaceuticals (Therapeutic Nuclear Medicine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Radiopharmaceuticals (Oncology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Radiopharmaceuticals (Oncology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Radiopharmaceuticals (Cardiology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Radiopharmaceuticals (Cardiology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Radiopharmaceuticals (Neurology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Radiopharmaceuticals (Neurology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Radiopharmaceuticals (Endocrinology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Radiopharmaceuticals (Endocrinology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Radiopharmaceuticals (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Radiopharmaceuticals (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Radiopharmaceuticals (Hospitals and Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Radiopharmaceuticals (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Radiopharmaceuticals (Research Institutes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Radiopharmaceuticals (Research Institutes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Radiopharmaceuticals (Diagnostic Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Radiopharmaceuticals (Diagnostic Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: North America: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: North America: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: United States: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: United States: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Canada: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Canada: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Asia-Pacific: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Asia-Pacific: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: China: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: China: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Japan: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Japan: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: India: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: India: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: South Korea: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: South Korea: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Australia: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Australia: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Indonesia: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Indonesia: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Others: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Others: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Europe: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Europe: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Germany: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Germany: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: France: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: France: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: United Kingdom: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: United Kingdom: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Italy: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Italy: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Spain: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Spain: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Russia: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Russia: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Latin America: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Latin America: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Brazil: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Brazil: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Mexico: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Mexico: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Middle East and Africa: Radiopharmaceuticals Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Middle East and Africa: Radiopharmaceuticals Market: Breakup by Country (in %), 2023
  • Figure 76: Middle East and Africa: Radiopharmaceuticals Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Global: Radiopharmaceuticals Industry: SWOT Analysis
  • Figure 78: Global: Radiopharmaceuticals Industry: Value Chain Analysis
  • Figure 79: Global: Radiopharmaceuticals Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Radiopharmaceuticals Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Radiopharmaceuticals Market Forecast: Breakup by Product Type (in Million US$), 2024-2032
  • Table 3: Global: Radiopharmaceuticals Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 4: Global: Radiopharmaceuticals Market Forecast: Breakup by End Use (in Million US$), 2024-2032
  • Table 5: Global: Radiopharmaceuticals Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Radiopharmaceuticals Market: Competitive Structure
  • Table 7: Global: Radiopharmaceuticals Market: Key Players